BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Belghiti J, Kianmanesh R. Surgical treatment of hepatocellular carcinoma. HPB (Oxford). 2005;7:42-49. [PMID: 18333160 DOI: 10.1080/13651820410024067] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Vullierme MP, Paradis V, Chirica M, Castaing D, Belghiti J, Soubrane O, Barbare JC, Farges O. Hepatocellular carcinoma--what's new? J Visc Surg. 2010;147:e1-e12. [PMID: 20595072 DOI: 10.1016/j.jviscsurg.2010.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
2 Liu HT, Cheng SB, Huang YC, Huang YT, Lin PT. Coenzyme Q10 and Oxidative Stress: Inflammation Status in Hepatocellular Carcinoma Patients after Surgery. Nutrients 2017;9:E29. [PMID: 28054958 DOI: 10.3390/nu9010029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 Mahmoud YI, Shehata AMM, Fares NH, Mahmoud AA. Spirulina inhibits hepatocellular carcinoma through activating p53 and apoptosis and suppressing oxidative stress and angiogenesis. Life Sci 2021;265:118827. [PMID: 33253720 DOI: 10.1016/j.lfs.2020.118827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Schoenberg MB, Hao J, Bucher JN, Miksch RC, Anger HJW, Mayer B, Mayerle J, Neumann J, Guba MO, Werner J, Bazhin AV. Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients. Cancers (Basel) 2018;10:E389. [PMID: 30340430 DOI: 10.3390/cancers10100389] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
5 Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM, Zheng SS. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29:1810-1816. [PMID: 21678027 DOI: 10.1007/s12032-011-0004-z] [Cited by in Crossref: 360] [Cited by in F6Publishing: 388] [Article Influence: 32.7] [Reference Citation Analysis]
6 Shen PC, Chang WC, Lo CH, Yang JF, Lee MS, Dai YH, Lin CS, Fan CY, Huang WY. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2019;105:307-18. [PMID: 31175903 DOI: 10.1016/j.ijrobp.2019.05.066] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
7 Chong YC, Toh TB, Chan Z, Lin QXX, Thng DKH, Hooi L, Ding Z, Shuen T, Toh HC, Dan YY, Bonney GK, Zhou L, Chow P, Wang Y, Benoukraf T, Chow EK, Han W. Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression. Hepatol Commun 2020;4:1362-81. [PMID: 32923839 DOI: 10.1002/hep4.1559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Li C, Liu JY, Peng W, Wen TF, Yan LN, Yang JY, Li B, Wang WT, Xu MQ. Liver resection versus transplantation for multiple hepatocellular carcinoma: a propensity score analysis. Oncotarget 2017;8:81492-500. [PMID: 29113408 DOI: 10.18632/oncotarget.20623] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Ramesh H. Resection for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S90-S96. [PMID: 25755617 DOI: 10.1016/j.jceh.2014.07.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
10 Kolarich AR, Cabrera R, Hughes SJ, George TJ, Geller BS, Grajo JR. Thermal ablation versus wedge or segmental resection in patients with early stage hepatocellular carcinoma: a population survival analysis. HPB 2019;21:249-57. [DOI: 10.1016/j.hpb.2018.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Li N, Jiang Y, Plantefève R, Michaud F, Nosrati Z, Tremblay C, Saatchi K, Häfeli UO, Kadoury S, Moran G, Joly F, Martel S, Soulez G. Magnetic Resonance Navigation for Targeted Embolization in a Two-Level Bifurcation Phantom. Ann Biomed Eng 2019;47:2402-15. [PMID: 31290038 DOI: 10.1007/s10439-019-02317-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Wu W, He X, Andayani D, Yang L, Ye J, Li Y, Chen Y, Li L. Pattern of distant extrahepatic metastases in primary liver cancer: a SEER based study. J Cancer 2017;8:2312-8. [PMID: 28819435 DOI: 10.7150/jca.19056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
13 Chapman WC, Klintmalm G, Hemming A, Vachharajani N, Majella Doyle MB, DeMatteo R, Zaydfudim V, Chung H, Cavaness K, Goldstein R. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220:628-637. [PMID: 25728142 DOI: 10.1016/j.jamcollsurg.2014.12.030] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 7.3] [Reference Citation Analysis]
14 Zhang Y, Guan DX, Shi J, Gao H, Li JJ, Zhao JS, Qiu L, Liu J, Li N, Guo WX. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer. J Hepatol. 2013;59:1255-1263. [PMID: 23867314 DOI: 10.1016/j.jhep.2013.07.009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
15 Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018;18:44. [PMID: 29568237 DOI: 10.1186/s12935-018-0538-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 19.0] [Reference Citation Analysis]
16 Khajeh E, Moghadam AD, Eslami P, Ali-hasan-al-saegh S, Ramouz A, Shafiei S, Ghamarnejad O, Dezfouli SA, Rupp C, Springfeld C, Carvalho C, Probst P, Mousavizadeh SM, Mehrabi A. Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09192-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Salgia R, Mendiratta V. The Multidisciplinary Management of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:405-8. [PMID: 34386204 DOI: 10.1002/cld.1068] [Reference Citation Analysis]
18 Aslam A, Kamath A, Spieler B, Maschiocchi M, Sabottke CF, Chernyak V, Lewis SC. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. Abdom Radiol (NY) 2021;46:3565-78. [PMID: 33856509 DOI: 10.1007/s00261-021-03076-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Park WK, Maxwell AW, Frank VE, Primmer MP, Collins SA, Baird GL, Dupuy DE. Evaluation of a Novel Thermal Accelerant for Augmentation of Microwave Energy during Image-guided Tumor Ablation. Theranostics 2017;7:1026-35. [PMID: 28382173 DOI: 10.7150/thno.18191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
20 Mizuguchi T, Kawamoto M, Meguro M, Hui TT, Hirata K. Preoperative liver function assessments to estimate the prognosis and safety of liver resections. Surg Today. 2014;44:1-10. [PMID: 23474700 DOI: 10.1007/s00595-013-0534-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
21 Kohno T, Morishita A, Iwama H, Fujita K, Tani J, Takuma K, Nakahara M, Oura K, Tadokoro T, Nomura T, Yoneyama H, Kato K, Okano K, Suzuki Y, Nishiyama A, Himoto T, Masaki T. Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma. Oncol Lett 2020;20:1727-33. [PMID: 32724415 DOI: 10.3892/ol.2020.11696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Wu Z, Guo W, Chen S, Zhuang W. Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy. Invest New Drugs 2021;39:394-9. [PMID: 33006020 DOI: 10.1007/s10637-020-01009-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 N'Kontchou G, Nault JC, Sutter O, Bourcier V, Coderc E, Grando V, Nahon P, Ganne-Carrié N, Diallo A, Sellier N, Seror O. Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results. Liver Cancer 2019;8:172-85. [PMID: 31192154 DOI: 10.1159/000489319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
24 Blumenfeld CM, Schulz MD, Aboian MS, Wilson MW, Moore T, Hetts SW, Grubbs RH. Drug capture materials based on genomic DNA-functionalized magnetic nanoparticles. Nat Commun 2018;9:2870. [PMID: 30030447 DOI: 10.1038/s41467-018-05305-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
25 Kaltenmeier CT, Yazdani H, van der Windt D, Molinari M, Geller D, Tsung A, Tohme S. Neutrophil extracellular traps as a novel biomarker to predict recurrence-free and overall survival in patients with primary hepatic malignancies. HPB (Oxford) 2021;23:309-20. [PMID: 32811764 DOI: 10.1016/j.hpb.2020.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Khan AS, Fowler KJ, Chapman WC. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 2014; 20(41): 15007-15017 [PMID: 25386049 DOI: 10.3748/wjg.v20.i41.15007] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
27 Tekbas A, Huebner J, Settmacher U, Dahmen U. Plants and Surgery: The Protective Effects of Thymoquinone on Hepatic Injury-A Systematic Review of In Vivo Studies. Int J Mol Sci 2018;19:E1085. [PMID: 29621129 DOI: 10.3390/ijms19041085] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
28 Wang CI, Chu PM, Chen YL, Lin YH, Chen CY. Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC. Int J Mol Sci 2021;22:13627. [PMID: 34948424 DOI: 10.3390/ijms222413627] [Reference Citation Analysis]
29 Cheung TT, Fan ST, Chu FS, Jenkins CR, Chok KS, Tsang SH, Dai WC, Chan AC, Chan SC, Yau TC, Poon RT, Lo CM. Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma. HPB (Oxford) 2013;15:567-73. [PMID: 23458602 DOI: 10.1111/hpb.12025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
30 Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, Cha S, Kamath P, Kim R, Nagorney DM. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005;9:1207-115; discussion 1215. [PMID: 16332475 DOI: 10.1016/j.gas20637944,] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Cheung TT, Wong TC, Chan SC. Technical note on ALPPS for a patient with advanced hepatocellular carcinoma associated with invasion of the inferior vena cava. Hepatobiliary Pancreat Dis Int 2016;15:319-23. [PMID: 27298110 DOI: 10.1016/s1499-3872(15)60414-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
32 Liu C, Liang P, Liu F, Wang Y, Li X, Han Z, Liu C. MWA combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma. Int J Hyperthermia. 2011;27:654-662. [PMID: 21966941 DOI: 10.3109/02656736.2011.605099] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
33 Melillo G, Chand V, Yovine A, Gupta A, Massacesi C. Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. Adv Ther 2021;38:2759-78. [PMID: 33881745 DOI: 10.1007/s12325-021-01675-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, Cha S, Kamath P, Kim R, Nagorney DM. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005;9:1207-1215; discussion 1215. [PMID: 16332475 DOI: 10.1016/j.gassur.2005.09.008] [Cited by in Crossref: 170] [Cited by in F6Publishing: 140] [Article Influence: 10.6] [Reference Citation Analysis]
35 Liu JP, Lerut J, Yang Z, Li ZK, Zheng SS. Three-dimensional modeling in complex liver surgery and liver transplantation. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00130-8. [PMID: 35701284 DOI: 10.1016/j.hbpd.2022.05.012] [Reference Citation Analysis]
36 Morishita A, Iwama H, Fujihara S, Sakamoto T, Fujita K, Tani J, Miyoshi H, Yoneyama H, Himoto T, Masaki T. MicroRNA profiles in various hepatocellular carcinoma cell lines. Oncol Lett 2016;12:1687-92. [PMID: 27588118 DOI: 10.3892/ol.2016.4853] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
37 Eriguchi T, Tsukamoto N, Kuroiwa N, Nemoto T, Ogata T, Okubo Y, Nakano S, Sugawara A. Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Pract Radiat Oncol 2021;11:44-52. [PMID: 32791232 DOI: 10.1016/j.prro.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Lee S, Kim SH. Reply to: “Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?”. Journal of Hepatology 2018;68:863-4. [DOI: 10.1016/j.jhep.2017.12.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
39 Eresen A, Yang J, Scotti A, Cai K, Yaghmai V, Zhang Z. Combination of natural killer cell-based immunotherapy and irreversible electroporation for the treatment of hepatocellular carcinoma. Ann Transl Med 2021;9:1089. [PMID: 34423001 DOI: 10.21037/atm-21-539] [Reference Citation Analysis]
40 Shen P, Huang W, Dai Y, Lo C, Yang J, Su Y, Wang Y, Lu C, Lin C. Radiomics-Based Predictive Model of Radiation-Induced Liver Disease in Hepatocellular Carcinoma Patients Receiving Stereo-Tactic Body Radiotherapy. Biomedicines 2022;10:597. [DOI: 10.3390/biomedicines10030597] [Reference Citation Analysis]
41 Eresen A, Sun C, Zhou K, Shangguan J, Wang B, Pan L, Hu S, Ma Q, Yang J, Zhang Z, Yaghmai V. Early Differentiation of Irreversible Electroporation Ablation Regions With Radiomics Features of Conventional MRI. Acad Radiol 2021:S1076-6332(21)00559-6. [PMID: 34933803 DOI: 10.1016/j.acra.2021.11.020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Nguyen GC, Thuluvath NP, Segev DL, Thuluvath PJ. Volumes of liver transplant and partial hepatectomy procedures are independently associated with lower postoperative mortality following resection for hepatocellular carcinoma. Liver Transpl. 2009;15:776-781. [PMID: 19562711 DOI: 10.1002/lt.21767] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
43 He ZL, Zheng H, Lin H, Miao XY, Zhong DW. Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World J Gastroenterol 2009; 15(33): 4177-4182 [PMID: 19725153 DOI: 10.3748/wjg.15.4177] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
44 Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler SJ, Zeleznik-Le NJ, Zhang J, Qiu W. FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis. Hepatology 2015;61:214-26. [PMID: 25163657 DOI: 10.1002/hep.27402] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 7.4] [Reference Citation Analysis]
45 Zhang L, Tu Y, He W, Peng Y, Qiu Z. A novel mechanism of hepatocellular carcinoma cell apoptosis induced by lupeol via Brain-Derived Neurotrophic Factor Inhibition and Glycogen Synthase Kinase 3 beta reactivation. Eur J Pharmacol. 2015;762:55-62. [PMID: 26004524 DOI: 10.1016/j.ejphar.2015.05.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
46 Liu C, Wang Y, Yu X, Dong B, Zhou P, Ren H, Liang P. Is percutaneous microwave ablation of liver tumor safe for patients with renal dysfunction. European Journal of Radiology 2011;79:e103-7. [DOI: 10.1016/j.ejrad.2011.04.050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Thornton RH, Covey A, Petre EN, Riedel ER, Maluccio MA, Sofocleous CT, Brody LA, Getrajdman GI, D’Angelica M, Fong Y. A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years. Cancer. 2009;115:5000-5006. [PMID: 19642175 DOI: 10.1002/cncr.24556] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
48 Carrapita J, Abrantes AM, Campelos S, Gonçalves AC, Cardoso D, Sarmento-Ribeiro AB, Rocha C, Santos JN, Botelho MF, Tralhão JG, Farges O, Barbosa JM. Impact of splenic artery ligation after major hepatectomy on liver function, regeneration and viability. Sci Rep 2016;6:34731. [PMID: 27725728 DOI: 10.1038/srep34731] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
49 Sun Y, Xu H, Chen X, Li X, Luo B. Inhibition of mitochondrial respiration overcomes hepatocellular carcinoma chemoresistance. Biochem Biophys Res Commun 2019;508:626-32. [PMID: 30522865 DOI: 10.1016/j.bbrc.2018.11.182] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
50 Ikeda S, Lim JS, Kurzrock R. Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. Mol Cancer Ther 2018;17:1114-22. [PMID: 29483209 DOI: 10.1158/1535-7163.MCT-17-0604] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 5.8] [Reference Citation Analysis]
51 Vitiello GA, Wang A, Lee RM, Russell MC, Yopp A, Ryon EL, Goel N, Luu S, Hsu C, Silberfein E, Correa-Gallego C, Berman RS, Lee AY. Surgical resection of early stage hepatocellular carcinoma improves patient survival at safety net hospitals. J Surg Oncol 2021;123:963-9. [PMID: 33497478 DOI: 10.1002/jso.26381] [Reference Citation Analysis]
52 Zarębska I, Gzil A, Durślewicz J, Jaworski D, Antosik P, Ahmadi N, Smolińska-Świtała M, Grzanka D, Szylberg Ł. The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. Clin Res Hepatol Gastroenterol 2021;45:101664. [PMID: 33667731 DOI: 10.1016/j.clinre.2021.101664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Li HY, Luo F, Li XY, Fu XF, He JF, Tian YZ, Zhu JJ, Chu XY, Zhao HL. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo. Anticancer Agents Med Chem 2019;19:740-9. [PMID: 30836927 DOI: 10.2174/1871520619666190301145637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol 2013;19:7316-26. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
55 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
56 Pugalenthi A, Cutter CS, Fong Y. Current treatment for small (< 5 cm) hepatocellular carcinoma: evolving roles for ablation and resection. Adv Surg 2014;48:97-114. [PMID: 25293610 DOI: 10.1016/j.yasu.2014.05.012] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
57 Nuciforo S, Heim MH. Organoids to model liver disease. JHEP Rep 2021;3:100198. [PMID: 33241206 DOI: 10.1016/j.jhepr.2020.100198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
58 Earl TM, Chapman WC. Conventional Surgical Treatment of Hepatocellular Carcinoma. Clinics in Liver Disease 2011;15:353-70. [DOI: 10.1016/j.cld.2011.03.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
59 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 256] [Article Influence: 69.7] [Reference Citation Analysis]
60 Jing R, Zhou X, Zhao J, Wei Y, Zuo B, You A, Rao Q, Gao X, Yang R, Chen L, Lu Z, Zhou Q, Zhang N, Yin H. Fluorescent peptide highlights micronodules in murine hepatocellular carcinoma models and humans in vitro. Hepatology 2018;68:1391-411. [PMID: 29405333 DOI: 10.1002/hep.29829] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
61 Harada K, Mizuguchi T, Katagiri Y, Kawamoto M, Nakamura Y, Meguro M, Ota S, Sasaki S, Miyanishi K, Sonoda T, Mori M, Shinomura Y, Kato J, Hirata K. Area between the hepatic and heart curves of (99m)Tc-galactosyl-human serum albumin scintigraphy represents liver function and disease progression for preoperative evaluation in hepatocellular carcinoma patients. J Hepatobiliary Pancreat Sci. 2012;19:667-673. [PMID: 22179579 DOI: 10.1007/s00534-011-0486-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
62 Zhou X, Li R, Jing R, Zuo B, Zheng Q. Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively. J Cancer Res Clin Oncol 2020;146:1509-21. [PMID: 32266537 DOI: 10.1007/s00432-020-03207-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
63 Aryal B, Yamakuchi M, Shimizu T, Kadono J, Furoi A, Gejima K, Komokata T, Koriyama C, Hashiguchi T, Imoto Y. Predictive Value of Diminished Serum PDGF-BB after Curative Resection of Hepatocellular Cancer. J Oncol 2019;2019:1925315. [PMID: 30723501 DOI: 10.1155/2019/1925315] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
64 Son Y, Shin NR, Kim SH, Park SC, Lee HJ. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. Int J Mol Sci 2021;22:5330. [PMID: 34069373 DOI: 10.3390/ijms22105330] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Huang IT, Dhungel B, Shrestha R, Bridle KR, Crawford DHG, Jayachandran A, Steel JC. Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma. Expert Opin Investig Drugs 2019;28:7-18. [PMID: 30474444 DOI: 10.1080/13543784.2019.1551359] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
66 Elsanousi OM, Abdellatief Mohamed M, Fadl AA. Operative outcome of liver resections for hepatocellular carcinoma: Retrospective case control study of a twelve-years pioneer experience in the Sudan. International Journal of Surgery Open 2018;10:37-42. [DOI: 10.1016/j.ijso.2017.11.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Ho C, Wu C, Lee P, Lai H, Ho M, Wu Y, Hu R. Analysis of the Risk Factors of Untransplantable Recurrence After Primary Curative Resection for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2013;20:2526-33. [DOI: 10.1245/s10434-013-2940-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
68 Zhang Q, Lou Y, Bai XL, Liang TB. Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies. World J Gastroenterol 2020; 26(26): 3720-3736 [PMID: 32774053 DOI: 10.3748/wjg.v26.i26.3720] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Morishita A, Fujita K, Iwama H, Chiyo T, Fujihara S, Oura K, Tadokoro T, Mimura S, Nomura T, Tani J, Yoneyama H, Kobayashi K, Kamada H, Guan Y, Nishiyama A, Okano K, Suzuki Y, Himoto T, Shimotohno K, Masaki T. Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol 2020;318:G401-9. [PMID: 31905024 DOI: 10.1152/ajpgi.00269.2019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
70 Ruzzenente A, Valdegamberi A, Campagnaro T, Conci S, Pachera S, Iacono C, Guglielmi A. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: Is liver resection always contraindicated? World J Gastroenterol 2011; 17(46): 5083-5088 [PMID: 22171142 DOI: 10.3748/wjg.v17.i46.5083] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
71 Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D;  American Hepato-Pancreato-Biliary Association;  Society of Surgical Oncology;  Society for Surgery of the Alimentary Tract. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:302-310. [PMID: 20590903 DOI: 10.1111/j.1477-2574.2010.00182.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
72 Thayer D, Noda C, Charalel R, Mills A, Chang R, Tao Y, Akinwande O. Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment. J Comp Eff Res 2018;7:343-56. [PMID: 29553286 DOI: 10.2217/cer-2017-0064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Nakano Y, Itano O, Shinoda M, Kitago M, Yagi H, Abe Y, Takeuchi A, Takemura Y, Kitagawa Y. Predictive factors for liver volume and function recovery after resection using three-dimensional analysis. HPB (Oxford) 2020;22:845-54. [PMID: 31680012 DOI: 10.1016/j.hpb.2019.10.002] [Reference Citation Analysis]
74 Pesce A, Scilletta R, Branca A, Nigro L, Montineri A, Larocca L, Fatuzzo F, Castaing M, Puleo S. Does transient elastography (FibroScan®) have a role in decision making in hepatocellular carcinoma? HPB (Oxford) 2012;14:403-8. [PMID: 22568417 DOI: 10.1111/j.1477-2574.2012.00465.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
75 Suh SW, Choi YS. Influence of liver fibrosis on prognosis after surgical resection for resectable single hepatocellular carcinoma. ANZ J Surg 2019;89:211-5. [PMID: 30117629 DOI: 10.1111/ans.14732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
76 Uhlig J, Sellers CM, Stein SM, Kim HS. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol. 2019;29:2679-2689. [PMID: 30560364 DOI: 10.1007/s00330-018-5902-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
77 Fang Y, Yi J, Lizhi L, Qiucheng C. Rho GDP dissociation inhibitor beta promotes cell proliferation and invasion by modulating the AKT pathway in hepatocellular carcinoma. DNA Cell Biol. 2014;33:781-786. [PMID: 25180836 DOI: 10.1089/dna.2014.2545] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
78 Bae A, Jung S, Lee J, Lee H, Park SG. Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy. Medicina 2022;58:155. [DOI: 10.3390/medicina58020155] [Reference Citation Analysis]
79 Kang KJ, Ahn KS. Anatomical resection of hepatocellular carcinoma: A critical review of the procedure and its benefits on survival. World J Gastroenterol 2017; 23(7): 1139-1146 [PMID: 28275294 DOI: 10.3748/wjg.v23.i7.1139] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
80 Cheng N, Wu J, Yin M, Xu J, Wang Y, Chen X, Nie Z, Yin J. LncRNA CASC11 promotes cancer cell proliferation in hepatocellular carcinoma by inhibiting miRNA-188-5p. Biosci Rep 2019;39:BSR20190251. [PMID: 30910841 DOI: 10.1042/BSR20190251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
81 Wang KX, Du GH, Qin XM, Gao L. Compound Kushen Injection intervenes metabolic reprogramming and epithelial-mesenchymal transition of HCC via regulating β-catenin/c-Myc signaling. Phytomedicine 2021;93:153781. [PMID: 34649212 DOI: 10.1016/j.phymed.2021.153781] [Reference Citation Analysis]
82 Kampalath R, Tran-Harding K, Do RKG, Mendiratta-Lala M, Yaghmai V. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. Magn Reson Imaging Clin N Am 2021;29:389-403. [PMID: 34243925 DOI: 10.1016/j.mric.2021.05.013] [Reference Citation Analysis]
83 Shukla J, Kalra N, Kumar R, Bhusari P, Chhabra A, Parmar M, Vatsa R, Singh H, Duseja A, Mittal BR. Two Cases of 188Re Microspheres for Inoperable Hepatocellular Carcinoma. Clin Nucl Med 2019;44:e93-5. [DOI: 10.1097/rlu.0000000000002373] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM, Zheng SS. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29:1810-1816. [PMID: 21678027 DOI: 10.1007/s12032-011-0004- z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]